Latest Financial Performance News

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Infratil Limited reported a robust FY2025 with operational EBITDAF nearing NZ$1 billion, driven by strong performances across its core infrastructure sectors and a strategic capital raise to fuel CDC Data Centres’ expansion.

Smartpay has reported an 8.5% rise in consolidated revenue for FY2025, driven by growth in Australia and a bold entry into New Zealand’s acquiring market. However, investments in technology and market expansion have weighed on EBITDA.

Smartpay Holdings Limited posted solid FY25 financials with revenue surpassing $104 million, driven by Australian market gains and promising New Zealand pilot progress. The company is advancing its trans-Tasman payments strategy amid regulatory developments.

Teaminvest Private Group has called off its planned acquisition of Enva Australia due to ongoing delays in meeting key conditions, though the move won’t affect its financials. The companies remain on good terms despite the termination.

Straker Ltd reports a solid FY25 performance marked by a strategic shift from legacy translation services to AI-powered language verification, underpinned by robust cash reserves and improved profitability.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited has announced an ordinary dividend of AUD 0.197 per share for the half-year ending March 2025, payable in July with flexible currency options for shareholders worldwide.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.

Straker Ltd has reported a record adjusted EBITDA of NZ$4.8 million for FY25, driven by strong growth in AI subscription services and operational efficiencies, even as overall revenue declined 10.3%. The company’s strategic pivot towards AI-powered offerings signals a promising shift in its business model.

ALS Limited reported a 16% revenue increase to nearly $3 billion in FY2025, driven by acquisitions and organic growth, while underlying net profit after tax dipped slightly. The company announced a $350 million equity raise to fund expansion and sustainability initiatives.